58th European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) Annual Meeting

Lille, France 24 June 2026 - 27 June 2026

$Maintenance upadacitinib efficacious in refractory paediatric UC$

Maintenance upadacitinib efficacious in refractory paediatric UC

19 Jul 2026 bởi

Maintenance treatment with upadacitinib helps sustain remission in children with refractory ulcerative colitis (UC), according to a retrospective study.

Maintenance upadacitinib efficacious in refractory paediatric UC

19 Jul 2026

Stopping anti-TNF therapy risky in paediatric IBD

18 Jul 2026 bởi

Paediatric inflammatory bowel disease (IBD) patients who have achieved clinical remission during tumour necrosis factor inhibitor (anti-TNF) therapy are likely to flare if they stop treatment, researchers from the IBD Porto Group of ESPGHAN has found.

Stopping anti-TNF therapy risky in paediatric IBD

18 Jul 2026

Bile acid reductions with odevixibat tied to improved LFTs in patients with PFIC2

16 Jul 2026 bởi

In individuals receiving odevixibat for progressive familial intrahepatic cholestasis 2 (PFIC2), otherwise known as bile salt export pump (BSEP) deficiency, reductions in serum bile acid (sBA) levels correlated with improvements in key liver function tests (LFTs), according to a post hoc subgroup analysis presented at ESPGHAN 2026.

Bile acid reductions with odevixibat tied to improved LFTs in patients with PFIC2

16 Jul 2026

Is whole goat milk formula protective against AD in infants?

14 Jul 2026 bởi

The results from the GIraFFE* study shed light on the potential protective effect of whole goat milk formula (WGF) against the development of atopic dermatitis (AD) in infants, compared with cow milk formula (CF).

Is whole goat milk formula protective against AD in infants?

14 Jul 2026

Long-term dupilumab sustains symptom improvements in paediatric EoE

13 Jul 2026 bởi

Treatment with dupilumab for up to 100 weeks reduces the frequency and severity of symptoms in children with eosinophilic esophagitis (EoE), as measured by the validated Pediatric Eosinophilic Esophagitis Symptom Score version 2.0 (PEESSv2.0), as shown by results of the open-label extension of the phase 3 EoE KIDS study.

Long-term dupilumab sustains symptom improvements in paediatric EoE

13 Jul 2026

Ustekinumab Q4W dosing induces response, remission in children with moderate-to-severe UC

12 Jul 2026 bởi

Paediatric patients with moderately to severely active ulcerative colitis (UC) show a favourable response to ustekinumab administered once every 4 weeks (Q4W), reports a study. This results in greater clinical response and remission associated with higher serum drug levels.

Ustekinumab Q4W dosing induces response, remission in children with moderate-to-severe UC

12 Jul 2026